• Sorafenib improves PFS in refractory desmoid tumors

    29 days ago - By Healio

    Patients with progressive, refractory or symptomatic desmoid tumors derived a significant PFS benefit from sorafenib, according to results of a double-blind, placebo-controlled randomized phase 3 study published in The New England Journal of Medicine.
    Sorafenib also included durable responses in this patient population, results showed. “In a retrospective analysis, sorafenib, an oral multitargeted receptor tyrosine kinase inhibitor, at a starting dose of 400 mg once daily was shown to have acceptable safety and was associated with a response rate of
    Read more ...

     

  • Dupilumab significantly improves asthma control

    29 days ago - By Healio

    Patients with uncontrolled, moderate-to-severe asthma treated with dupilumab demonstrated significant improvement in asthma control regardless of exacerbation history, according to data presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
    “Dupilumab, a fully human anti-interleukin -4 receptor a monoclonal antibody, inhibiting IL-4/IL-13 signaling pathways, key drivers of type 2 inflammation, is approved for treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis,” Jonathan Corren, MD, from David Geffen
    Read more ...